… date, four SHP2 allosteric inhibitors have entered clinical trials for the treatment of solid
tumors… This review will provide a summary of the physiological and biological functions of SHP2 …

… Although a similar mechanism has not yet been reported for solid tumors, we cannot
exclude that it contributes, jointly to the hypermethylation, to the PTPN6 gene silencing. …

… SHP2, and briefly review the development of SHP2 inhibitors. … and synergistic tumor
immunotherapy using SHP2 inhibitors. … used to treat solid tumors such as NSCLC, colorectal …

… of combinations with a novel SHP2 inhibitor (PF-07284892/ARRY-558) … to treating patients
with a SHP2 inhibitor alone in dose escalation, each patient with an oncogene-driven cancer …

… solid tumor malignancies. One recent study demonstrates that combined pharmacologic
inhibition of SHP2 … NF1-deficient malignant peripheral nerve sheath tumors (MPNST). This article…

… of SHP2. More importantly, we also summarize the role of SHP2 in different solid tumor entities
and their tumor … clinical trials with allosteric SHP2 inhibitors and discuss opportunities and …

… Increasing evidences have suggested that dysregulation of SHP2 contributes to … and solid
tumors with less frequency, making SHP2 a promising therapeutic target for cancer treatment (…

… that cells with constitutively activated RAS signalling would be insensitive to SHP2 inhibition.
To test this hypothesis, SHP2-dependent SUM52 cells were transduced with a lentivirus …

RMC-4630 is a potent, selective, orally bioavailable allosteric inhibitor of SHP2, a central
node regulating RAS signaling. Consistent with preclinical observations, initial data from a …

… effect of the SHP2 inhibitor on T cells in vivo, and further, the impact of SHP2 inhibition on
the … The potential for SHP2 inhibitors to provide therapeutic benefit in solid tumors bearing …